ARRY - アレイ・バイオファ―マ （Array BioPharma Inc.） アレイ・バイオファ―マARRYのチャート
ARRYの企業情報
| symbol | ARRY |
|---|---|
| 会社名 | Array BioPharma Inc. （アレイ・バイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アレイ・バイオファーマ（Array BioPharma Inc.）は、癌に罹患した患者を治療するための標的化された小分子薬物の発見、開発、および商業化に焦点を当てた生物医薬品会社である。同社のプログラムには、約3種類のがん剤、ビニメチニブ、エンコラフェニブおよびセルメチニブ（AstraZeneca、PLCと提携）が含まれている。そのビニメチニブおよびエンコラフェニブは進行癌患者の第III相試験中であり、BRAF突然変異メラノーマ患者のビニメチニブと併用してエンコファニブを試験するCOLUMBUS試験を含み、BRAF V600E突然変異結腸直腸癌（BRAFm CRC）患者のビシメチニブおよびセツキシマブと組み合わせてエンコラフェニブを試験するBEACON CRC試験を開始した。そのセルメチニブは、癌のためのマイトジェン活性化プロテインキナーゼ（MEK）阻害剤であり、これは第III相試験中である。同社の先進的な臨床段階の薬剤には、Filanesib、ARRY-797、ASC08 / Danoprevir、Ipatasertib / GDC-0068、Motolimod / VTX-2337、LOXO-101、ONT-380 / ARRY-380、GDC-0575、GDC-0994およびARRY -382が含まれる。 アレイ・バイオファ―マは、米国のバイオ医薬品会社。主に癌患者の治療向け低分子薬の発見、開発、商業化に従事。全額出資の臨床段階の薬剤は、多発性骨髄腫のためのキネシンスピンドルタンパク質阻害剤ARRY-520、ラミンA / C関連の拡張型心筋症のためのp38阻害剤ARRY-79など。本社はコロラド州ボ―ルダ―。 Array Technologies is a leading global technology company providing tracker solutions and services for utility-scale solar energy projects as one of the world's largest manufacturers of ground-mounted systems. With efficient installation and terrain flexibility coupled with high reliability, durability, and performance, Array delivers a lower levelized cost of energy. The Company's focus on innovation, combined with its customer-centric approach, has helped achieve some of the industry's best returns. Array Technologies is headquartered in the United States with offices in Europe, Central America, and Australia. |
| 本社所在地 | 3200 Walnut Street Boulder CO 80301 USA |
| 代表者氏名 | Carrie S. Cox キャリーS.コックス |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 303-381-6600 |
| 設立年月日 | 35827 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2000年 |
| 従業員数 | 298人 |
| url | www.arraybiopharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/arry |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -127.69100 |
| 終値（lastsale） | 13.665 |
| 時価総額（marketcap） | 2909574880.185 |
| 時価総額 | 時価総額（百万ドル） 3291.769 |
| 売上高 | 売上高（百万ドル） 173.76800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2991.057 |
| 当期純利益 | 当期純利益（百万ドル） -147.34600 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Array Biopharma Inc revenues increased 15% to $173.8M. Net loss increased 26% to $147.3M. Revenues reflect Asia Pacific segment increase from $3.8M to $46.1M. Higher net loss reflects General and administrative increase of 49% to $58.5M (expense) Realized gains on investments and other decrease of 92% to $69K (income). |
ARRYのテクニカル分析
ARRYのニュース
New Commerce memo suggests acceleration of solar panel probe - report 2022/05/04 20:20:59 Kwhen Finance
Array Technologies, Inc. Announces First Quarter 2022 Earnings Release Date and Conference Call 2022/05/03 13:41:00 GlobeNewswire
ALBUQUERQUE, N.M., May 03, 2022 (GLOBE NEWSWIRE) -- Array Technologies, Inc. (the “Company” or “Array”) (Nasdaq: ARRY) today announced that the company will release its first quarter 2022 results after the market close on Tuesday, May 10 th , 2022, to be followed by a conference call at 5:00 p.m. (Eastern Time) on the same day.
Tuesday’s Upgrades and Downgrades: Amgen, Array Technologies, Boeing, Carvana, DocuSign, Enterprise Products Partners, Fiserv, Johnson Controls, Monster Beverage, Nvidia, PayPal, PG&E, T-Mobile, Uber Technologies 2022/05/03 12:54:59 24/7 Wall street
Tuesday''s top analyst upgrades and downgrades included Amgen, Array Technologies, Boeing, Carvana, DocuSign, Enterprise Products Partners, Fiserv, Johnson Controls, Monster Beverage, Nvidia, PayPal, PG&E, T-Mobile and Uber Technologies.
Where Array Technologies Stands With Analysts 2022/05/02 19:07:49 Benzinga
Within the last quarter, Array Technologies (NASDAQ: ARRY ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 0 0 1 0 0 1M Ago 2 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Array Technologies. The company has an average price target of $20.0 with a high of $30.00 and a low of $14.00. Below is a summary of how these 4 analysts rated Array Technologies over the past 3 months. The greater the number of … Full story available on Benzinga.com
Array Technologies slams ''reckless'' U.S. solar modules probe (NASDAQ:ARRY) 2022/04/25 20:24:05 Seeking Alpha
Array Technologies (ARRY) said Monday it is "disappointed" by the U.S
Lawson Products, Houghton Mifflin Harcourt lead postmarket gainers; Rhythm Pharma top... 2022/01/14 22:04:41 Seeking Alpha
Gainers: Lawson Products (LAWS) +7%, Houghton Mifflin Harcourt HMHC +5%, Provention Bio (PRVB) +3%, Array Technologies (ARRY) +3%, People''s United Financial (PBCT) +2%.Losers:
Clearside Biomedical, Ebix lead postmarket gainers; Perella Weinberg Partners among lo... 2022/01/13 22:22:45 Seeking Alpha
Gainers: Clearside Biomedical (CLSD) +13%, Ebix (EBIX) +7%, Cipher Mining (CIFR) +6%, Array Technologies (ARRY) +5%, Amicus Therapeutics (FOLD) +4%. Losers: Perella Weinberg…
Array Technologies: Debt Overview 2022/01/13 14:51:45 Benzinga
Shares of Array Technologies (NASDAQ: ARRY ) decreased by 29.62% in the past three months. Before having a look at the importance of debt, let us look at how much debt Array Technologies has. Array Technologies''s Debt Based on Array Technologies''s balance sheet as of November 12, 2021, long-term debt is at $299.21 million and current debt is at $4.30 million, amounting to $303.51 million in total debt. Adjusted for $116.39 million in cash-equivalents, the company''s net debt is at $187.12 million. Let''s define some of the terms we used in the paragraph above. Current debt is the portion of a company''s debt which is due within 1 year, while long-term Full story available on Benzinga.com
MainStay VP Natural Resources Portfolio Buys Exxon Mobil Corp, Alcoa Corp, Nutrien, Sells ... 2021/12/23 18:38:02 GuruFocus
Related Stocks: NTR , TROX , XOM , AA , CHK , SLB , DAR , NHY , K , CTVA , AGI , CF , ENEL , RRC , COP , NEM , CVA , CNX , ARRY , NEL ,
SHAREHOLDER ALERT: Robbins LLP is Investigating Array Technologies, Inc. (ARRY) on Behalf of Shareholders 2021/07/21 18:59:00 Business Wire
Shareholder rights law firm Robbins LLP is investigating Array Technologies, Inc. (NASDAQ: ARRY) to determine whether certain Array officers and direc
Carnegie Capital Asset Management, LLC Buys Shoals Technologies Group Inc, Guardant Health Inc, ... 2021/07/17 00:38:06 GuruFocus
Related Stocks: GH , ARRY , XBI , ARKK , TEL , IQLT , SHLS , IBMK , BLL , IBMJ , IGSB , AZN , PRAH , BTZ , KMX , CODI , ECPG , HTGC ,
ARRY Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Array Technologies, Inc. Shareholders With Losses Exceeding $500K of Class Action and Lead Plaintiff Deadline: July 13, 2021 2021/07/13 15:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Array Technologies, Inc. ("Array" or the "Company") (NASDAQ: ARRY) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Array securities: (1) pursuant and/or traceable to the Companys October 2020 initial public offering (the "IPO"), or (2) pursuant and/or traceable to the Companys December 2020 off
Array Technologies Appoints Supply Chain Veteran Ken Stacherski as Senior Vice President of Operations 2021/07/13 13:00:00 Intrado Digital Media
Stacherski joins Array with over 30 years of supply chain experience Stacherski joins Array with over 30 years of supply chain experience
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Array Technologies, Inc. (ARRY) 2021/07/12 14:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ARRY #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Array Technologies, Inc. (ARRY)